NEXGEL, Inc. (NXGL)
NASDAQ: NXGL · Real-Time Price · USD
0.606
-0.001 (-0.16%)
At close: Apr 28, 2026, 4:00 PM EDT
0.594
-0.012 (-2.05%)
Pre-market: Apr 29, 2026, 5:28 AM EDT
NEXGEL Employees
NEXGEL had 19 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
19
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$601,105
Profits / Employee
-$157,895
Market Cap
5.14M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Harvard Bioscience | 339 |
| Jin Medical International | 273 |
| Retractable Technologies | 227 |
| Bionano Genomics | 97 |
| Femasys | 54 |
| Nephros | 36 |
| Milestone Scientific | 15 |
| Cuprina Holdings (Cayman) Limited | 14 |
NXGL News
- 7 days ago - NEXGEL Transcript: M&A announcement - Transcripts
- 11 days ago - NEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ET - GlobeNewsWire
- 13 days ago - NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction - GlobeNewsWire
- 20 days ago - NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction - GlobeNewsWire
- 4 weeks ago - NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity - GlobeNewsWire
- 6 weeks ago - NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products - GlobeNewsWire
- 7 weeks ago - NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products - GlobeNewsWire
- 7 weeks ago - EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple Revenue - Benzinga